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Abstract
Background/Objectives The epidemiology of exocrine pancreatic insufficiency (EPI) after acute pancreatitis (AP) is uncer-
tain. We sought to determine the prevalence, progression, etiology and pancreatic enzyme replacement therapy (PERT) 
requirements for EPI during follow-up of AP by systematic review and meta-analysis.
Methods Scopus, Medline and Embase were searched for prospective observational studies or randomized clinical trials 
(RCTs) of PERT reporting EPI during the first admission (between the start of oral refeeding and before discharge) or follow-
up (≥ 1 month of discharge) for AP in adults. EPI was diagnosed by direct and/or indirect laboratory exocrine pancreatic 
function tests.
Results Quantitative data were analyzed from 370 patients studied during admission (10 studies) and 1795 patients dur-
ing follow-up (39 studies). The pooled prevalence of EPI during admission was 62% (95% confidence interval: 39–82%), 
decreasing significantly during follow-up to 35% (27–43%; risk difference: − 0.34, − 0.53 to − 0.14). There was a two-fold 
increase in the prevalence of EPI with severe compared with mild AP, and it was higher in patients with pancreatic necrosis 
and those with an alcohol etiology. The prevalence decreased during recovery, but persisted in a third of patients. There 
was no statistically significant difference between EPI and new-onset pre-diabetes/diabetes (risk difference: 0.8, 0.7–1.1, 
P = 0.33) in studies reporting both. Sensitivity analysis showed fecal elastase-1 assay detected significantly fewer patients 
with EPI than other tests.
Conclusions The prevalence of EPI during admission and follow-up is substantial in patients with a first attack of AP. Unan-
swered questions remain about the way this is managed, and further RCTs are indicated.
Keywords Acute pancreatitis · Exocrine pancreatic insufficiency · Pancreatic enzyme replacement therapy · Necrotizing 
pancreatitis · Severe pancreatitis
Introduction
Patients presenting with acute pancreatitis (AP) are at risk 
of local and systemic complications, some of which persist 
beyond the hospital admission [1]. This includes both endo-
crine and exocrine pancreatic insufficiency (EPI). Recent 
studies have shown that prediabetes and diabetes mellitus 
(DM) occur following the first attack of AP in up to 40% 
patients and increase over 5 years [2]; they are associated 
with a marked reduction in the quality of life [3, 4]. Another 
study found that 10% of first-attack AP patients will then 
develop chronic pancreatitis [5]. A recent meta-analysis [6] 
investigated EPI after AP, but not during hospital admis-
sion, and found that a quarter of all AP patients develop EPI 
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during follow-up. The risk of EPI is higher when patients 
have alcoholic etiology, severe and necrotizing pancreatitis.
The prevalence of EPI following AP and the use of pan-
creatic enzyme replacement therapy (PERT) are variably 
reported in the literature. The aim of this study was to under-
take a systematic review and meta-analysis to determine the 
prevalence of EPI using formal exocrine function tests dur-
ing AP hospitalization and follow-up to determine the con-
tributing factors and time course and define strategies for 
PERT to treat EPI after AP.
Methods
Data Sources and Searches
This study adhered to the Preferred Reporting Items for Sys-
tematic Reviews and Meta-analyses (PRISMA) criteria [7]. 
Electronic databases (Scopus, Embase and Medline) were 
searched (IB-R, CC-S and JL-N) for relevant studies from 
1 January 1946 to 31 July 2018. References from searched 
studies were also examined. The keywords are listed in 
Supplementary Methods. Two authors (WH and DdlI-G) 
scrutinized all identified studies independently and agreed 
on those for inclusion. Citations from included studies and 
relevant reviews were also evaluated. When there was a dis-
crepancy, the senior authors (JED-M and RS) arbitrated.
Study Selection
Included studies fulfilled the following criteria: (1) pro-
spective observational studies or randomized clinical tri-
als (RCTs) of PERT that reported on EPI during the index 
admission (between the start of oral refeeding and before 
discharge) or follow-up (≥ 1 month after discharge) for AP in 
adults; (2) EPI diagnosed by direct and/or indirect laboratory 
exocrine function tests [8, 9]; (3) with multiple publications 
with overlapping patient groups the most recent study was 
included unless an earlier study had a larger sample size. 
Editorials, expert opinions, reviews, abstracts, case reports, 
letters, small sample size (< 10 patients), pre-existing EPI, 
population-based studies and retrospective studies were 
excluded.
Data Extraction and Quality Assessment
Two authors (WH and DdlI-G) independently collected 
data from included studies using a standardized pro forma 
designed by two senior authors (JED-M and RS). The 
data items are provided in Supplementary Methods. Three 
authors (XZ, NS and WC) independently scored the included 
studies, and two further authors (WH and DdlI-G) resolved 
any disagreement. The quality of observational studies was 
assessed using the Newcastle-Ottawa scale [10] with a total 
score ≥ 5 (up to 4 for selection, 2 for comparability and 3 for 
outcome) indicative of high quality; the quality of RCTs was 
assessed using the Jadad system [11] with a total score ≥ 3 
(randomization 0 or 1; allocation concealment 0 or 1; double 
blinding 0, 1 or 2; recording of dropouts and/or withdrawals 
0 or 1) indicative of high quality.
Outcomes of Interest
The primary outcome was the number (proportion) of 
patients diagnosed with EPI following development of AP 
during both hospitalization for the first attack of AP and 
follow-up. EPI was diagnosed by either direct pancreatic 
function tests, including the Lundh meal test, secretin-caer-
ulein (or pancreozymin) test (SCT), amino acid consump-
tion test (AACT), fecal chymotrypsin test or fecal elastase-1 
(FE-1) test, or indirect tests including the triolein breath test, 
serum fluorescein-dilaurate test, serum pancreolauryl test, 
urinary pancreolauryl test, urinary N-benzoyl-l-tyrosyl-
P-aminobenzoic acid (NBP-PABA) test, urinary d-xylose 
excretion test and fecal fat excretion (FFE) test. An FE-1 
of 100–200 µg/g was defined as mild to moderate EPI and 
< 100 µg/g as severe EPI.
Secondary outcomes included symptoms of EPI [12], 
treatment with PERT [12], recurrence of AP [1, 13], new-
onset prediabetes and/or DM [2, 14], changes in pancreatic 
morphology, quality of life and employment status.
Definition of AP Severity, Complications 
and Pancreatic Intervention
AP was classified as severe when fulfilling one or more of 
the following criteria: (1) the “severe” category of the origi-
nal Atlanta classification (OAC) [15]; (2) the “moderately 
severe” and “severe” grades of the revised Atlanta classi-
fication (RAC) [16]; (3) the presence of necrosis (> 30%), 
pseudocyst or abscess; (4) a clinical severity score, imaging 
severity indices or biomarkers greater than their respective 
cutoff values. Other cases of AP were classified as mild. 
Studies were analyzed separately if they only included 
infected pancreatic necrosis (IPN), and IPN was defined as 
those with definitive diagnosis of pancreatic infection [17] 
and/or unresolving sterile necrosis that was treated by pan-
creatic necrosectomy that became infected [17, 18]. Necro-
sectomy included open and minimally invasive procedures, 
while conservative management included no procedure, per-
cutaneous drainage or an endoscopic procedure only [19].
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Data Synthesis and Statistical Analysis
Pooled data were expressed as prevalence with 95% confi-
dence interval (CI). Data for two group comparisons were 
expressed as relative risk (RR) or risk difference (RD) with 
95% CI. Stats Direct V3.1 (StatsDirect Ltd, Cheshire, UK) 
was used to generate forest plots of pooled data using a 
random effects model to deliver the most conservative esti-
mates. Heterogeneity was evaluated using χ2. P < 0.1 was 
considered significant. Statistical heterogeneity was assessed 
using I2 values with cutoffs of 25%, 50% and 75% to indi-
cate low, moderate and high heterogeneity, respectively [20]. 
Meta-analyses generated the RR and RD for each compari-
son between two groups. For studies of EPI during the index 
admission and follow-up, the prevalence of EPI during the 
index admission was compared with EPI during follow-up 
between gallstone versus alcohol etiology and OAC mild 
versus severe AP. For all the follow-up studies, the preva-
lence of EPI was compared between females versus males; 
gallstones versus alcohol etiology; OAC mild versus severe 
AP; RAC mild versus moderate to severe AP; edematous 
versus necrotizing AP; necrosis < 50% versus necrosis 
≥ 50%; necrosis in the head versus body and/or tail; con-
servative management versus necrosectomy. Pooled preva-
lence of recurrent AP, pre-diabetes and/or DM and pancre-
atic morphologic changes were also generated.
Subgroup analyses examined high-quality studies, studies 
with sample sizes ≥ 40, Western population, etiology (gall-
stone or alcohol) and follow-up periods (up to 12 months, > 
12–36 months, > 36–60 months and > 60 months). Sensi-
tivity analyses considered studies restricted to first AP epi-
sodes, pre-existing DM, studies with a proportion of patients 
undergoing pancreatic intervention for necrosis and/or infec-
tion during the index admission, direct EPI tests, indirect 
EPI tests, FFE test only and FE-1 test only.
Meta-regression analyses determined the impact of publi-
cation year, patient age, gender, AP etiology, disease sever-
ity, type of EPI test and study quality on the pooled preva-
lence estimate using Stata SE version 13 software (StataCorp 
LP, College Station TX, USA); P < 0.05 was considered sig-
nificant. Publication bias was assessed visually by funnel 
plots [21] and using P values generated from the pooled 
prevalence of EPI during index admission and follow-up 
as well as by subgroups according to Begg-Mazumdar [22] 
and Egger et al. [23]; P < 0.05 was considered significant.
Results
Characteristics of Included Studies
A PRISMA flow diagram for study selection is shown in 
Fig. 1. A final total of 41 studies [24–64] from 16 countries 
were included. The study designs are summarized in Table 1. 
Thirty-seven studies were published in English, two [27, 29] 
in Spanish, one [41] in Italian and one [59] in Russian. There 
were two RCTs [30, 55] for PERT versus placebo and one 
for the endoscopic versus surgical step-up approach [64]. 
Ten studies [36, 44, 46, 47, 49, 51, 53, 54, 57, 64] had a 
consecutive cohort design, and the remainders were non-
consecutive cohort studies. Three studies [55, 56, 64] were 
multicenter. The shortest median follow-up was 1 month 
[27] and the longest 180 months [51]. Ten studies [25, 27, 
29–31, 40, 44, 48, 49, 55] assessed EPI during hospitaliza-
tion and 39 studies [24–48, 50–54, 56–64] during follow-up.
Of the 38 studies scored by the Newcastle-Ottawa scale 
with Selection, Comparability and Outcome compositions 
(Supplementary Table 1A), 32 (84%) were of high qual-
ity [24–29, 31–54, 56–62, 64]. The three RCTs [30, 55, 
64] were all of high quality (Supplementary Table 1B). 
Regarding the Selection section, 22 (58%) studies had no 
“selection of the non-exposed cohort,” while 35 (92%) did 
not report “demonstration that outcome of interest was not 
present at start of study.” In the Comparability section, 33 
(87%) did not show “comparability of cohorts on the basis 
of the design or analysis.” In the Outcome section, ten had 
no “adequacy of follow-up of cohorts.”
Fig. 1  Preferred reporting items for the systematic reviews flow chart 
of study selection for this systematic review
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Characteristics of Included Patients
The overall baseline characteristics of patients are shown 
in Table 2. For ten inpatient studies, the pooled median 
age was 51 years (males, 59%); etiology was 70% gall-
stones, 17% alcohol and 13% other causes; six studies 
were restricted to first AP episodes [30, 31, 40, 44, 48, 
49], while four [25, 27, 29, 55] did not report. For the 
39 follow-up studies, the pooled median age was 51 years 
(males, 63%); etiology was 55% gallstone, 28% alcohol 
and 17% other causes; 16 studies were restricted to first 
AP episodes [30–34, 39, 40, 43–46, 48, 50, 53, 57, 60], 
while 5 [28, 35, 38, 56, 62] were not so restricted, and the 
remaining 18 [24–27, 29, 36, 37, 41, 42, 47, 51, 52, 54, 
58, 59, 61, 63, 64] did not report.
Pancreatic Function During Admission 
and Follow‑Up
Detailed pancreatic function data and clinical outcomes at 
follow-up are shown in Table 3. For the 10 inpatient stud-
ies, 1 [48] reported pre-existing DM in 8 of 54 patients 
(15%), 2 [40, 49] reported none, and the remaining stud-
ies [25, 27, 29–31, 44, 55] did not report; 2 [44, 49] had 
a proportion of patients who had undergone pancreatic 
interventions, 4 [25, 30, 31, 40] had none, and 4 [27, 29, 
48, 55] did not report.
In the 39 follow-up studies, body mass index, alcohol 
history, cigarette smoking and symptoms of EPI were rarely 
recorded (data not shown). Nine studies [24, 38, 48, 51, 52, 
54, 60, 61, 64] had a minor proportion of pre-existing DM 
(1.3–18%), 8 [40, 46, 47, 50, 53, 57, 58, 62] had none, and 
the remaining 22 [25–37, 39, 41–45, 56, 59, 63] did not 
report; 22 [26, 28, 32, 33, 37, 38, 42, 44–47, 50–54, 57–59, 
61, 62] had a proportion of patients who had undergone pan-
creatic interventions; 10 [25, 30, 31, 34, 39–41, 43, 60, 63] 
reported no pancreatic interventions, and the remaining 7 
[24, 27, 29, 35, 36, 48, 56] did not report.
Results of the Meta‑Analysis
There were insufficient data for quantitative meta-analysis of 
the effects of PERT versus placebo in the two RCTs [30, 55]. 
The results of meta-analysis are shown in Table 4.
Prevalence of EPI During Admission and Follow‑Up
In the 10 index admission studies, 389 patients were enrolled 
and 370 analyzed (Supplementary Figure 1A). The pooled 
prevalence of EPI was 62% (95% CI 39–82%), with high sta-
tistical heterogeneity among studies (I2 = 95%). Of the eight 
studies [25, 27, 29–31, 40, 44, 48] that also provided data on 
EPI during follow-up, the pooled prevalence of EPI was 71% 
(50–89%) during the index admission and 33% (17–53%) 
during follow-up, respectively (Supplementary Figure 1B 
and 1C), showing that the prevalence of EPI halved (RD: 
− 0.34, − 0.53 to − 0.14) during follow-up (Fig. 2a).
Five studies [25, 27, 29, 31, 49] of EPI during the index 
admission compared alcohol versus gallstone etiology (RR: 
1.79, 0.59–5.43, P = 0.35; Fig. 2b), and three [25, 40, 49] 
compared OAC severe versus mild AP (RR: 2.9, 0.5–16.7, 
P = 0.24; Fig. 2c), both showing no significant difference. No 
data were quantitively synthesized for gender and necrosis.
Prevalence of EPI During Follow‑Up Alone
In the 39 follow-up studies, 2168 patients were enrolled and 
1795 analyzed (Table 4 and Supplementary Figure 2). The 
pooled prevalence of EPI was 35% (27–43%), with high sta-
tistical heterogeneity among studies (I2 = 92%). The pooled 
prevalence of EPI was 21% for OAC mild AP (13 studies) 
(Supplementary Figure 3A), 42% for OAC severe AP (23 
studies) (Supplementary Figure 3B), 16% for RAC mild AP 
(4 studies) (Supplementary Figure 4A), 27% for RAC mod-
erately severe AP (2 studies) (Supplementary Figure 4B) 
and 30% for RAC severe AP (3 studies) (Supplementary 
Figure 4C). The pooled prevalence of EPI was 24% for 
edematous AP (8 studies) (Supplementary Figure 5A), 47% 
for necrotizing AP (15 studies) (Supplementary Figure 5B) 
and 48% for IPN (11 studies) (Supplementary Figure 5C).
There was no significant difference in the prevalence of 
EPI during follow-up for gender (RR: 1.5, 0.4–6.3, P > 0.5; 
3 studies) [46, 47, 56] (Table 4). There was a significantly 
higher prevalence of EPI for patients with alcohol etiology 
compared with gallstones (RR: 1.6, 1.1–2.3, P = 0.01; 11 
studies) [26, 28, 29, 31, 33–35, 43, 46, 47, 56, 61] (Fig. 3a). 
There was a higher prevalence of EPI in patients with OAC 
severe AP versus mild AP (RR: 1.5, 1.2–2, P = 0.003, 10 
studies) [40, 45, 48, 52–54, 56, 60–62] (Fig. 3b); in RAC 
moderately severe/severe versus mild AP (RR: 2, 1.1–3.4, 
P = 0.018, 3 studies) [56, 61, 62] (Fig. 3c); in necrotizing 
versus edematous AP (RR: 1.8, 1–3.2, P = 0.06; 6 studies) 
[28, 40, 43, 50, 54, 62] (Fig. 4a). There was no significant 
difference in the prevalence of EPI for ≥ 50% necrosis versus 
< 50% necrosis (RR: 1.2, 1–1.6, P = 0.172, 6 studies) [28, 
40, 46, 47, 50, 62] (Fig. 4b), for pancreatic head versus body 
and/or tail necrosis (RR: 1.1, 0.6–2, P > 0.5; 3 studies) [46, 
47, 62] (Table 4) or for patients having necrosectomy versus 
conservative management (RR: 1.62, 0.8–3.44, P = 0.205; 5 
studies) [42, 50, 58, 59, 64] (Fig. 4c).
The pooled prevalence for recurrent AP, pre-diabetes 
and/or DM and pancreatic morphologic changes was 24% 
(17–31%), 38% (31–45%) and 36% (27–45%), respectively 
(Table 4). In the studies [24, 26, 28, 34, 37–42, 44–48, 
50–52, 54, 56–62] that reported on the occurrence of EPI 
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Table 4  Results of meta-analyses
EPI exocrine pancreatic insufficiency, CI confidence interval, OAC original Atlanta classification, RAC revised Atlanta classification, IPN 
infected pancreatic necrosis, AP acute pancreatitis, DM diabetic mellitus
a Included studies that simultaneously reported prevalence of EPI during index admission and at follow-up
b Included studies that simultaneously reported prevalence of EPI and prediabetic and/or DM
Variable No. of studies No. of patients No. of EPI Effect estimate Heterogeneity
Pool prevalence, 
% (95% CI)
I2 (%) P value
Overall during index admission 10 370 183 62 (39–82) 95 < 0.0001
 Index admission versus follow-upa
  Index admission 8 240 154 71 (50–89) 92 < 0.0001
  Follow-up 8 210 69 33 (17–53) 88 < 0.0001
 Mild versus severe (OAC)
  Mild 3 101 34 46 (0–99) 98 < 0.0001
  Severe 3 27 13 66 (11–99) 90 < 0.0001
 Biliary versus alcohol
  Biliary etiology 5 116 51 72 (26–99) 96 < 0.0001
  Alcohol etiology 6 87 50 87 (71–97) 26 0.248
Overall at follow-up 39 1795 618 35 (27–43) 91 < 0.0001
 Mild versus severe (OAC)
  Mild 13 467 100 21 (11–33) 89 < 0.0001
  Severe 23 847 345 42 (33–52) 86 < 0.0001
 Mild versus moderate to severe (RAC)
  Mild 4 160 24 16 (10–23) 23 0.275
  Moderate 2 27 7 27 (13–45) 0 0.453
  Severe 3 208 58 30 (15–47) 82 0.004
 Biliary versus alcohol
  Biliary etiology 15 335 72 22 (12–33) 81 < 0.0001
  Alcohol etiology 14 388 155 44 (27–60) 91 < 0.0001
  Other etiologies 3 72 13 19 (11–29) 0 0.726
 Female versus male
  Female 3 45 6 23 (1–64) 79 0.01
  Male 5 119 45 48 (26–71) 82 0.0003
 Edematous versus necrotizing versus IPN
  Edematous 8 261 54 24 (14–36) 77 < 0.0001
  Necrotizing 15 538 244 47 (36–58) 84 < 0.0001
  IPN 11 398 188 48 (35–62) 86 < 0.0001
 Necrosis < 50% versus necrosis ≥ 50%
  < 50% 6 121 49 41 (17–68) 86 < 0.0001
  ≥ 50% 6 81 45 58 (34–79) 76 0.001
 Head versus body and/or tail
  Head 3 20 8 41 (22–62) 0 0.661
  Body/tail 3 79 27 34 (11–61) 70 0.036
 Conservative versus necrosectomy
  Conservative 4 74 16 23 (12–35) 24 0.267
  Necrosectomy 9 183 73 48 (32–63) 77 < 0.0001
 Recurrent AP 13 937 188 24 (17–31) 82 < 0.0001
 Prediabetic and/or DM versus  EPIb
  Prediabetes and/or DM 27 1454 494 38 (31–45) 87 < 0.0001
  EPI 27 1357 409 32 (24–40) 90 < 0.0001
 Pancreatic morphologic changes 18 810 272 36 (27–45) 87 < 0.0001
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and new-onset pre-diabetes and/or DM, the pooled preva-
lence of EPI was 32% (24–40%), without any statistically 
significant difference between the two (RR of EPI in patients 
developing new-onset pre-diabetes and/or DM: 0.8, 0.7–1.1, 
P = 0.33) (Fig. 5).
In eight studies [40, 46, 53, 54, 56, 59, 61, 62] that 
reported the severity of EPI and used the FE-1 test, the 
pooled prevalence of mild to moderately severe EPI was 
16% (CI 10–24%) (Supplementary Figure 6A) and of severe 
EPI was 11% (CI 6–17% (Supplementary Figure 6B).
Fig. 2  Relative risk comparison for prevalence of exocrine pancreatic 
insufficiency during index admission of acute pancreatitis: a index 
admission versus follow-up, b biliary versus alcohol (original Atlanta 
classification, OAC) and c mild versus severe (OAC)
Fig. 3  Relative risk comparison for prevalence of exocrine pancreatic 
insufficiency for all follow-up studies of acute pancreatitis: a biliary 
versus alcohol (original Atlanta classification, OAC), b mild versus 
severe (OAC) and c mild versus moderate to severe (revised Atlanta 
classification, RAC)
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The prevalence of EPI for long-term follow-up is shown 
in Fig. 6 and Supplementary Table 2. These data demon-
strate that there was a steady decrease in the prevalence of 
EPI after AP from the index admission over the subsequent 
5 years of follow-up (OAC severe AP 59–38%, OAC mild 
AP 56–18%), but beyond 5 years there was a modest rise in 
prevalence.
Subgroup Analyses
Subgroup analyses found that study quality, sample size and 
Western population did not affect the primary meta-analysis 
results (Supplementary Table 2). Gallstone etiology had a 
decreased prevalence of EPI compared with the primary 
analysis, whereas alcohol etiology had an increased preva-
lence of EPI. None of these factors significantly affected the 
statistical heterogeneity.
Sensitivity Analyses
Sensitivity analyses found that in the studies that used 
the FE-1 test there was a lower pooled prevalence of EPI 
(Supplementary Table 3). In contrast, the sensitivity analy-
ses found that the primary meta-analysis results were not 
affected by restriction to first episodes of AP, the proportion 
of patients with pre-existing DM, the proportion of patients 
who had undergone pancreatic intervention or the use of 
direct, indirect or FFE tests to diagnose EPI. None of these 
factors significantly affected statistical heterogeneity.
Meta‑regression Analysis
Meta-regression analyses did not identify any significant 
contributing factor to study heterogeneity by any pre-defined 
criterion except the year of publication for the follow-up 
study (Supplementary Table 4).
Publication Bias
Funnel plots for publication bias are shown in Supplemen-
tary Figure 6. There was no publication bias identified for 
admission studies (n = 10), follow-up studies (n = 39) or 
OAC severe AP patients (Begg-Mazumdar and Egger tests 
P > 0.1). There was significant publication bias for the 
follow-up studies of OAC mild AP patients (both Begg-
Mazumdar and Egger tests P < 0.05).
Discussion
By combining data from a total of 41 studies, we found 
EPI in over half (62%) of all AP patients during their index 
admission, including patients of all grades of severity. One 
Fig. 4  Relative risk comparison for prevalence of exocrine pancreatic 
insufficiency at follow-up focused on acute necrotizing pancreatitis: a 
edematous versus necrotizing; b necrosis < 50% versus ≥ 50%; c con-
servative management (mgt) versus necrosectomy
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third (35%) of all AP patients were found to have EPI during 
follow-up, significantly more after severe AP compared with 
mild AP or necrotizing AP compared with edematous AP. 
Note that EPI was not restricted to patients who had exten-
sive pancreatic necrosis, as almost half (46%) of patients 
who had mild AP were found to have EPI during their index 
admission and one fifth during follow-up. Patients who had 
pancreatic necrosis ≥ 50%, underwent necrosectomy and 
head necrosectomy had increased, but not statistically sig-
nificantly, RR of EPI compared with those who had necro-
sis < 50%, conservative procedures and body/tail necrosec-
tomy, respectively. The prevalence of EPI and new-onset 
pre-diabetes/diabetes was similar in studies reporting both 
complications.
There was a progressive decrease in the prevalence of 
EPI during the follow-up period, to about half at 5 years. 
Beyond 5 years, prevalence rose modestly, which may have 
resulted from a focus on more severe and/or progressive 
disease evidenced by biased reports for mild AP from our 
publication bias analysis. These data show that recovery 
from EPI after AP may take many months. AP can be asso-
ciated with patchy necrosis of many different cell types in 
the pancreatic parenchyma, exacerbated in inflammation, 
with disruption of the normal microscopic architecture and 
Fig. 5  Relative risk comparison 
for prevalence of exocrine pan-
creatic insufficiency (EPI) ver-
sus pre-diabetes and/or diabetes 
mellitus (DM) for all follow-up 
studies of acute pancreatitis that 
reported these two parameters 
simultaneously
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complex, coordinated machinery of secretion [65]. The high 
prevalence of EPI in patients with AP during their index 
admission is consistent with such microscopic changes and 
their effects on exocrine function. There are many data indi-
cating that the murine exocrine pancreas has the capacity to 
recover or regenerate after experimental AP, but no direct 
evidence of human exocrine pancreatic regeneration after 
AP has previously been provided [65]. There is thus a nota-
ble and consistent decrease in the prevalence of EPI over 
the first 12 months after index admission, which is likely 
to result from resolution of inflammation, repair, remod-
eling and regeneration. However, it is also noteworthy that 
at 5 years this recovery remains incomplete in over a third 
of affected patients, including 15–20% of all those who had 
mild AP. In these patients EPI persists and can increase in 
the long term.
Estimates of the prevalence of EPI after AP made with-
out formal exocrine function tests may be misleading. For 
example, a large population-based study [66] from Taiwan 
included 12,284 patients after a first episode of AP, of whom 
94% had OAC mild AP and 46% were prescribed PERT for 
EPI during follow-up. A US multicenter retrospective study 
of 167 patients found 30 (28%) of 106 who had a first epi-
sode of necrotizing AP were subsequently prescribed PERT 
for EPI [67]. In contrast, an Italian multicenter retrospective 
questionnaire study of 631 patients found 10 (2%) of 558 
who had OAC mild AP and 6 (8%) of 73 who had severe 
AP developed overt steatorrhea [68]. In a meta-analysis 
investigating the relationship between exocrine and endo-
crine failure after AP [14], summary data from a total of 
8 studies including 234 patients identified new-onset pre-
diabetes and/or DM in 91 (41% of 221 identified by stand-
ard criteria or requirement for therapy) and EPI (by either 
formal exocrine function testing or reported requirement for 
PERT) in 59 (27% of 220). This study did not explore the 
impact of gender, etiology or AP severity, EPI during the 
index admission, the progression of EPI over time, the role 
of PERT or the potential effects of EPI on quality of life. The 
recent meta-analysis by Hollemans et al. [6] used diagnostic 
laboratory testing for EPI and found a pooled prevalence of 
EPI was 27.1% of 1495 AP patients analyzed at 36 months 
(median).
An alcohol etiology had a twofold RR for EPI after AP 
compared with other etiologies. This is consistent with the 
repeated injury that occurs with prolonged and excessive 
consumption of alcohol [69] with the risk of atrophy and 
fibrosis. In these patients there is an increased risk of recur-
rent AP and/or chronic pancreatitis [12]. Smoking, more 
common among those who consume excess alcohol, is 
known to increase the risk of chronic pancreatitis [70–72]. 
Given that repair and the reduction in EPI occurs over many 
months, it is important to cease alcohol consumption and 
to maintain prolonged abstinence. This is supported by the 
low incidence of EPI (6%) during long-term follow-up of 
abstinent patients who had alcohol-associated AP [73].
Regarding testing (direct and indirect) for EPI, all the 
tests found similar prevalence rates for EPI except FE-1. 
This was used in more recent studies and identified a sig-
nificantly lower prevalence of EPI. While the FE-1 test is 
easy to perform and cost-effective for RAC severe patients 
(sensitivity and specificity > 90%) [74], the sensitivity for 
RAC mild/moderately severe AP is low (~60%) and fails to 
identify many patients with EPI.
Subgroup and sensitivity analyses did not alter our find-
ings, despite the significant heterogeneity between studies. 
Tests used to diagnose EPI contributed to this heterogene-
ity, but it was not possible to determine the contribution 
of the definitions and methods of identification of etiology, 
application of severity classification, follow-up periods and 
time points of investigation. Nor did we contact authors for 
further data, as we considered it highly unlikely that this 
would alter our principal findings.
The prevalence and persistence of EPI after AP indicate 
that up to a third of patients are at risk of malnutrition and 
malabsorption for prolonged periods after AP, and they 
may well increase after 5 years. AP induces many catabolic 
responses, resolution of which EPI may delay; the longer 
EPI persists, the greater the potential impact of malabsorp-
tion and malnutrition; thus, early PERT requirement may be 
indicated. Hollemans et al. [6] and our findings confirm that 
EPI may develop after AP of any severity, justifying routine 
symptom enquiry and a simple test of exocrine pancreatic 
function during follow-up, e.g., the FE-1 test.
Apart from the limitations reported by Hollemans et al. 
[6] for such a meta-analysis, different methods used to meas-
ure EPI may create the high heterogeneity between studies. 
Also, healthy inequalities that may cause unexplained het-
erogeneity were rarely reported by the included studies. This 
Fig. 6  Time course of the pooled prevalence of exocrine pancreatic 
insufficiency during and for > 5  years after an attack of acute pan-
creatitis obtained from all included studies
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study also highlighted the high prevalence of EPI during 
AP admission regardless of disease severity, and there was 
a lack of studies to investigate the effect of PERT on EPI 
during admission and at follow-up.
In conclusion, there is a significant and largely unrecog-
nized prevalence of EPI after AP. Taking into account the 
data from this study and other published studies, a number 
of practical recommendations can be made:
1. EPI should be tested for in all patients with AP before 
discharge from index admission, irrespective of the pre-
dicted severity.
2. PERT may be considered for patients with persistent 
EPI (e.g., FE-1 < 100–200 µg/g) after AP has resolved. 
Patients who were likely to develop persistent EPI 
included those with moderately severe and severe AP, 
those with pancreatic necrosis, those who have had a 
necrosectomy and those with an alcohol etiology.
3. Re-testing for EPI (off treatment) should be done at 
3 months after discharge in all patients, e.g., a normal 
FE-1 test result would mean that PERT can be discon-
tinued. For those who remain on PERT, testing should 
be repeated at 6 and 12 months.
These recommendations will require prospective valida-
tion studies, but withholding PERT until further evidence is 
available is not justified. Further research is needed to refine 
diagnostic methods for EPI, to determine optimal PERT 
strategies and to address the impact of health inequalities.
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